primary biliary cholangitis
Hepatology · 2018–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| elafibranor Primary biliary cholangitis (PBC) in patients with elevated alkaline phosphatase and bilirubin who have inadequate response to ursodeoxycholic acid (UDCA) or… | Mar 2025 | Recommended with restriction | 1 individuals Liver Foundation |
| seladelpar Treatment of primary biliary cholangitis in patients with inadequate response to ursodeoxycholic acid (UDCA) or intolerance to UDCA. | Dec 2025 | Deferred | input received Liver Foundation |
| seladelpar Treatment of primary biliary cholangitis in patients with inadequate response to ursodeoxycholic acid (UDCA) or intolerance to UDCA. | Dec 2025 | Deferred | input received Liver Foundation |
| ursodeoxycholic acid Primary biliary cholangitis (PBC), an autoimmune disease of the liver requiring chronic, long-term treatment. | Mar 2023 | Recommended | input received |
| obeticholic acid Primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in UDCA inadequate responders and as monotherapy in patients intolerant to UDCA. | Mar 2021 | Recommended with restriction | none received |
| obeticholic acid Primary biliary cholangitis, for patients with inadequate response to ursodeoxycholic acid (UDCA) or intolerant to UDCA due to severe side effects. | Nov 2020 | Deferred | 1 individuals |
| obeticholic acid Treatment of primary biliary cholangitis in patients with inadequate response to ursodeoxycholic acid (UDCA) or who are intolerant to UDCA. | Jul 2019 | Not recommended | 31 individuals PBC Foundation |
| obeticholic acid Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy… | Nov 2018 | Not recommended | none received |
Who spoke
Liver Foundation · PBC Foundation
What the PBS pays
$31M in government benefit over 2024–25, across 78,030 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ursodeoxycholic acid | $17.9M |
| obeticholic acid | $13.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 3 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| seladelparSeladelpar for previously treated primary biliary cholangitis | TA1171 | recommended | 2026-06 |
| elafibranorElafibranor for previously treated primary biliary cholangitis | TA1016 | recommended | 2024-11 |
| obeticholic acidObeticholic acid for treating primary biliary cholangitis | TA443 | recommended restricted | 2017-04 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.